In the wake of the first global COVID‐19 wave, concerns were raised as to the safety of ACE inhibitors and angiotensin receptor blockers (ARBs), because preclinical data demonstrated that these drugs result in increased ACE2 expression.4, 5, 6. This evidence concerns the gene ACE2 and COVID-19.